Clinical trial
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent…
NCT00005855 · New Approaches to Brain Tumor Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00005855 |
|---|---|
| Title | Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma |
| Official title | A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma |
| Lead sponsor | New Approaches to Brain Tumor Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | carmustine, efaproxiral |
| Enrollment | 48 |
| Start date | Jul 1, 2000 |
| Completion | Oct 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: